105 related articles for article (PubMed ID: 28695331)
21. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129
[TBL] [Abstract][Full Text] [Related]
22. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
[TBL] [Abstract][Full Text] [Related]
23. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
Marks PA; Breslow R
Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
[TBL] [Abstract][Full Text] [Related]
24. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
25. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
Kalanxhi E; Risberg K; Barua IS; Dueland S; Waagene S; Andersen SN; Pettersen SJ; Lindvall JM; Redalen KR; Flatmark K; Ree AH
Cancer Res Treat; 2017 Apr; 49(2):374-386. PubMed ID: 27488871
[TBL] [Abstract][Full Text] [Related]
26. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
27. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
28. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.
Duvic M; Vu J
Biologics; 2007 Dec; 1(4):377-92. PubMed ID: 19707308
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
32. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
33. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Chiaradonna F; Barozzi I; Miccolo C; Bucci G; Palorini R; Fornasari L; Botrugno OA; Pruneri G; Masullo M; Passafaro A; Galimberti VE; Fantin VR; Richon VM; Pece S; Viale G; Di Fiore PP; Draetta G; Pelicci PG; Minucci S; Chiocca S
Antioxid Redox Signal; 2015 Jul; 23(1):15-29. PubMed ID: 25897982
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
36. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
37. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
39. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
40. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.
Chao MW; Lai MJ; Liou JP; Chang YL; Wang JC; Pan SL; Teng CM
J Hematol Oncol; 2015 Jul; 8():82. PubMed ID: 26156322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
